XML 30 R21.htm IDEA: XBRL DOCUMENT
v3.22.1

Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract] |
Schedule of Derivative Liabilities at Fair Value | The following table presents the changes in the development derivative liability for the three months ended March 31, 2022 and 2021:
|  |  |  | Three months ended March 31,
|  | Fair Value Hierarchy Level |  | 2022 |  | 2021
Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively |  | 3 |  | $ | 27,726 |  |  | $ | — |
Non-cash research and development expense |  |  |  | 4,951 |  |  | 2,248 |
Cash receipts from SFJ |  |  |  | 750 |  |  | 750 |
Change in the fair value of development derivative liability |  |  |  | (33,427) |  |  | 1,599 |
Fair value at end of period |  | 3 |  | $ | — |  |  | $ | 4,597 |

X
- References No definition available. + Details
Name: | us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of derivative liabilities at fair value. + References No definition available. + Details
Name: | us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration